Napo Pharmaceuticals’ New Mytesi Video Calls Attention to the Continuing Widespread Problem of Diarrhea in People Living With HIV/AIDS
Napo’s Mytesi® product is approved by the U.S.
“Chronic, symptomatic diarrhea remains a major, underreported
consequence of HIV and a significant burden for HIV patients. In fact, a
recent study shows that one in five people living with HIV experience
diarrhea1. Many HIV patients are only aware of
over-the-counter drugs as treatments for diarrhea. These agents have not
been studied specifically in people living with HIV/AIDS. In addition,
Imodium® and Lomotil®—opioids that work by slowing
movement through the GI tract—can cause constipation. Mytesi®
is the only drug studied in and
A communication disconnect between physicians and their patients may be one of the major reasons diarrhea among people living with HIV/AIDS remains underrecognized. These patients have often been dealing with diarrhea due to HIV enteropathy for a long time and just assume it is something they must live with. Physicians don’t typically have diarrhea at the top of their list of issues to discuss with patients. Additionally, it is estimated that only one-third of HIV patients with diarrhea receive treatment, and they may be inappropriately and unsatisfactorily using an over-the-counter drug that their healthcare provider is unaware of1. Many physicians and HIV patients may not be aware that a specific treatment, Mytesi®, is available. The “Enough is Enough” Mytesi® tagline appearing in the video is meant to indicate that diarrhea does not have to become the new normal.
Mytesi® (crofelemer) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi® is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi®. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).
More information and complete Prescribing Information are available at Mytesi.com.
Crofelemer, the active ingredient in Mytesi®, is a
botanical (plant-based) drug extracted and purified from the red bark
sap of the medicinal Croton lechleri tree in the
Jaguar has filed with the
For more information about Jaguar, please visit www.jaguaranimalhealth.com.
Certain statements in this press release constitute “forward-looking
statements.” These include statements regarding the proposed merger of
Jaguar and Napo, the expectation that the proposed merger will close by
the end of
1Gehrig, M. et al. Actual versus perceived use of
pharmacokinetic (primarily absorption) influential OTC agents and ART
tolerability in a nationwide matched cohort of HIV patients and their
healthcare providers, IDWeek 2016 Poster Abstract Session: HIV:
KCSA Strategic Communications
Garth Russell, 212-896-1250